Modified cell vesicles trigger 'lipid counterstorm' against lung inflammation in mice
Researchers have created a treatment called SPLEV, derived from liver cell vesicles and treated with an enzyme, to combat cytokine storms in mice. This approach shows promise in suppressing severe systemic inflammation associated with respiratory diseases.
Why it matters
Cytokine storms are a life-threatening complication of various infections; this research offers a potential new therapeutic pathway for managing severe inflammatory responses.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Lipid-induced counter-storms mediated by SPLEVs suppressed the tissue inflammation score. Credit: Ai Kotani The COVID-19 pandemic highlighted severe consequences of unchecked respiratory disease, including cytokine storms. This phenomenon affected many COVID-19 patients and is a potential side effect of many other diseases involving significant inflammation, but approaches to treating these symptoms remain unclear.
Researchers from the University of Osaka and other institutions report that a specially treated cell-derived product called a SPLEV strongly protects against the effects of cytokine storms. The findings have been published in Science Advances .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in